An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer.
about
Single group study to evaluate the feasibility and complications of radiofrequency ablation and usefulness of post treatment position emission tomography in lung tumoursNear-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice.Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome?From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803.Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study.A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET.Advances in radiological staging of non-small cell lung cancer (NSCLC).(18)FDG PET-CT standardized uptake value for the prediction of radiation pneumonitis in patients with lung cancer receiving radiotherapy.[18F-fluorodeoxyglucose positron emission tomography in the diagnosis of lung cancer]Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance.
P2860
Q24797179-31315CB7-99AA-4A4E-8496-894ADFA91330Q33243608-3789F319-2EF4-4FFA-8A5B-1373908F60CCQ33372250-E62CEB8D-EEC7-4835-97FD-FBEC917CCA89Q33776980-F14C699A-E337-4AE6-8143-4C94376CC88CQ34978457-C01690E6-0EF5-4EE3-8551-9775BEEE196AQ36545344-F743B457-4B83-4575-BE92-D85413696C98Q36991571-18D9B245-8461-4616-8E58-A4715D60F05CQ38537051-2C3A326D-704A-49EB-ACC4-AEE9675BB70FQ40202907-FF4BC5F2-0BED-4612-80F7-A65C62888CB6Q41973755-0A235630-8CD5-4480-BBE4-FD498E8E51A1Q42736347-37E9FE6F-B673-4907-B0F1-602E512DDC3DQ44266130-91FE8D86-CAD7-4EAD-A8DF-C409B5DBDBF3Q46150817-A01D75BB-05A4-4941-9888-447F3DBE8D71Q52987662-3FB7C19E-40F0-4968-9191-66C100627D37Q53292813-2A5EF850-A995-4356-9FF1-1E68B4BF0D98
P2860
An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
An initial experience with FDG ...... ction therapy for lung cancer.
@en
An initial experience with FDG ...... ction therapy for lung cancer.
@nl
type
label
An initial experience with FDG ...... ction therapy for lung cancer.
@en
An initial experience with FDG ...... ction therapy for lung cancer.
@nl
prefLabel
An initial experience with FDG ...... ction therapy for lung cancer.
@en
An initial experience with FDG ...... ction therapy for lung cancer.
@nl
P2093
P1476
An initial experience with FDG ...... ction therapy for lung cancer.
@en
P2093
Manjit Bains
Michelle S Ginsberg
Mithat Gonen
Robert J Downey
Robert J Ginsberg
Robert Korst
Steven M Larson
Tim Akhurst
Valerie W Rusch
P304
259-64; discussion 264-6
P356
10.1016/S0003-4975(01)03257-X
P407
P577
2002-01-01T00:00:00Z